Revenue
2023
2024
2025
CG Oncology, Inc. (CGON)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $4.0M | $1.1M | $204,000 |
| Research & development | $116.6M | $82.1M | $45.8M |
| Operating expenses | $194.8M | $115.8M | $55.7M |
| Operating income | −$190.8M | −$114.7M | −$55.4M |
| EBITDAderived | −$189.3M | −$114.6M | −$55.4M |
| Net income | −$161.0M | −$88.0M | −$48.6M |
| Basic EPSper diluted share | -$2.08 | -$1.41 | -$15.65 |
| Diluted EPSper diluted share | -$2.08 | -$1.41 | -$15.65 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Liu Brian Guan-ChyunDirector | BuyCommon Stock · indirect | 371.1K | $66.87 | $24.81M | 1.89M |
| Jun 24, 2026Form 4 · 10b5-1 | POST LEONARD EDirector | SellCommon Stock | 5.0K | $70.00 | $350.0K | 0 |
| Jun 22, 2026Form 4 · 10b5-1 | POST LEONARD EDirector | SellCommon Stock | 5.0K | $65.00 | $325.0K | 0 |
| Jun 15, 2026Form 4 · 10b5-1 | Mulay JamesDirector | SellCommon Stock | 1.3K | $60.12 | $78.8K | 0 |
| Jun 15, 2026Form 4 · 10b5-1 | Mulay JamesDirector | SellCommon Stock | 654 | $60.12 | $39.3K | 0 |